Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.

Alexander M, Pavlakis N, John T, O'Connell R, Kao S, Hughes BGM, Lee A, Hayes SA, Howell VM, Clarke SJ, Millward M, Burbury K, Solomon B, Itchins M.

Lung Cancer. 2020 Jan 22;142:34-40. doi: 10.1016/j.lungcan.2020.01.017. [Epub ahead of print]

PMID:
32087434
2.

EGFR mutations in lung cancer: not all equal in the eyes of the immune system?

Fong KM, Hughes BGM, Lwin Z, Yang IA.

Ann Transl Med. 2019 Dec;7(Suppl 8):S326. doi: 10.21037/atm.2019.09.132. No abstract available.

3.

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).

Ahern E, Cubitt A, Ballard E, Teng MWL, Dougall WC, Smyth MJ, Godbolt D, Naidoo R, Goldrick A, Hughes BGM.

Trials. 2019 Dec 19;20(1):753. doi: 10.1186/s13063-019-3951-x.

4.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

5.

Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer.

Ratnayake G, Shanker M, Roberts K, Mason R, Hughes BGM, Lwin Z, Jain V, O'Byrne K, Lehman M, Chua B.

Asia Pac J Clin Oncol. 2020 Feb;16(1):56-62. doi: 10.1111/ajco.13242. Epub 2019 Nov 12.

PMID:
31721446
6.

An update: circulating tumor cells in head and neck cancer.

Kulasinghe A, Hughes BGM, Kenny L, Punyadeera C.

Expert Rev Mol Diagn. 2019 Dec;19(12):1109-1115. doi: 10.1080/14737159.2020.1688145. Epub 2019 Nov 7.

PMID:
31680565
7.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators.

Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Erratum in: Lancet. 2020 Jan 25;395(10220):272.

PMID:
31679945
8.

Evaluation of a speech pathology service delivery model for patients at low dysphagia risk during radiotherapy for HNC.

Moroney LB, Ward EC, Helios J, Crombie J, Burns CL, Blake C, Comans T, Chua B, Kenny L, Hughes BGM.

Support Care Cancer. 2019 Jul 27. doi: 10.1007/s00520-019-04992-x. [Epub ahead of print]

PMID:
31352509
9.

The ENHANCES study: a randomised controlled trial of a nurse-led survivorship intervention for patients treated for head and neck cancer.

Turner J, Yates P, Kenny L, Gordon LG, Burmeister B, Hughes BGM, McCarthy AL, Perry C, Chan RJ, Paviour A, Skerman H, Batstone M, Mackenzie L.

Support Care Cancer. 2019 Dec;27(12):4627-4637. doi: 10.1007/s00520-019-04748-7. Epub 2019 Apr 2.

PMID:
30941580
10.

Patterns of care for stage III non-small cell lung cancer in Australia.

Parente P, Chan BA, Hughes BGM, Jasas K, Joshi R, Kao S, Hegi-Johnson F, Hui R, McLaughlin-Barrett S, Nordman I, Stone E.

Asia Pac J Clin Oncol. 2019 Jun;15(3):93-100. doi: 10.1111/ajco.13140. Epub 2019 Mar 14. Review.

PMID:
30868747
11.

Doxorubicin induces de novo expression of N-terminal-truncated matrix metalloproteinase-2 in cardiac myocytes.

Chan BYH, Roczkowsky A, Moser N, Poirier M, Hughes BG, Ilarraza R, Schulz R.

Can J Physiol Pharmacol. 2018 Dec;96(12):1238-1245. doi: 10.1139/cjpp-2018-0275. Epub 2018 Oct 11.

PMID:
30308129
12.

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.

Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, John T.

J Thorac Oncol. 2018 Nov;13(11):1784-1791. doi: 10.1016/j.jtho.2018.08.007. Epub 2018 Aug 22.

13.

Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns.

Moroney LB, Helios J, Ward EC, Crombie J, Burns CL, Yeo SQ, Pelecanos A, Spurgin AL, Blake C, Kenny L, Chua B, Hughes BGM.

Support Care Cancer. 2019 Feb;27(2):573-581. doi: 10.1007/s00520-018-4352-5. Epub 2018 Jul 17.

PMID:
30019149
14.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.

15.

Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns.

Moroney LB, Helios J, Ward EC, Crombie J, Pelecanos A, Burns CL, Spurgin AL, Blake C, Kenny L, Chua B, Hughes BGM.

Head Neck. 2018 Sep;40(9):1955-1966. doi: 10.1002/hed.25182. Epub 2018 May 13.

PMID:
29756244
16.

Estimating the occurrence of primary ubiquinone deficiency by analysis of large-scale sequencing data.

Hughes BG, Harrison PM, Hekimi S.

Sci Rep. 2017 Dec 18;7(1):17744. doi: 10.1038/s41598-017-17564-y.

17.

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L, Hughes BGM.

Target Oncol. 2018 Feb;13(1):89-98. doi: 10.1007/s11523-017-0543-0.

PMID:
29188408
18.

Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer.

Brown T, Banks M, Hughes BGM, Lin C, Kenny LM, Bauer JD.

Oral Oncol. 2017 Sep;72:17-25. doi: 10.1016/j.oraloncology.2017.06.025. Epub 2017 Jul 5.

PMID:
28797454
19.

Tube feeding during treatment for head and neck cancer - Adherence and patient reported barriers.

Brown T, Banks M, Hughes BGM, Lin C, Kenny L, Bauer J.

Oral Oncol. 2017 Sep;72:140-149. doi: 10.1016/j.oraloncology.2017.07.017. Epub 2017 Jul 25.

PMID:
28797450
20.

Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.

Roberts K, Culleton V, Lwin Z, O'Byrne K, Hughes BG.

Asia Pac J Clin Oncol. 2017 Aug;13(4):277-288. doi: 10.1111/ajco.12698. Epub 2017 Jul 12. Review.

PMID:
28699304
21.

Many possible maximum lifespan trajectories.

Hughes BG, Hekimi S.

Nature. 2017 Jun 28;546(7660):E8-E9. doi: 10.1038/nature22786. No abstract available.

PMID:
28658230
22.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S.

Eur J Cancer. 2017 Sep;82:27-33. doi: 10.1016/j.ejca.2017.05.019. Epub 2017 Jul 10.

PMID:
28646771
23.

Randomised controlled trial of early prophylactic feeding vs standard care in patients with head and neck cancer.

Brown TE, Banks MD, Hughes BGM, Lin CY, Kenny LM, Bauer JD.

Br J Cancer. 2017 Jun 27;117(1):15-24. doi: 10.1038/bjc.2017.138. Epub 2017 May 23.

24.

Investigation of p16 status, chemotherapy regimen, and other nutrition markers for predicting gastrostomy in patients with head and neck cancer.

Brown TE, Wittholz K, Way M, Banks MD, Hughes BG, Lin CY, Kenny LM, Bauer JD.

Head Neck. 2017 May;39(5):868-875. doi: 10.1002/hed.24630. Epub 2017 Feb 23.

PMID:
28230929
25.

Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study.

Hughes BG, Ahern E, Lehman M, Pratt G, Dauth M, Pritchard W, Wockner L, Horwood K.

Asia Pac J Clin Oncol. 2017 Jun;13(3):137-144. doi: 10.1111/ajco.12649. Epub 2017 Feb 9.

PMID:
28181415
26.

Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin.

Nottage MK, Lin C, Hughes BG, Kenny L, Smith DD, Houston K, Francesconi A.

Head Neck. 2017 Apr;39(4):679-683. doi: 10.1002/hed.24662. Epub 2016 Dec 29.

PMID:
28032670
27.

Patterns of dysphagia and acute toxicities in patients with head and neck cancer undergoing helical IMRT±concurrent chemotherapy.

Moroney LB, Helios J, Ward EC, Crombie J, Wockner LF, Burns CL, Spurgin AL, Blake C, Kenny L, Hughes BG.

Oral Oncol. 2017 Jan;64:1-8. doi: 10.1016/j.oraloncology.2016.11.009. Epub 2016 Nov 25.

PMID:
28024718
28.

Comparison of Nutritional and Clinical Outcomes in Patients with Head and Neck Cancer Undergoing Chemoradiotherapy Utilizing Prophylactic versus Reactive Nutrition Support Approaches.

Brown TE, Banks MD, Hughes BGM, Lin CY, Kenny LM, Bauer JD.

J Acad Nutr Diet. 2018 Apr;118(4):627-636. doi: 10.1016/j.jand.2016.10.013. Epub 2016 Dec 13.

PMID:
27986517
29.

Different Mechanisms of Longevity in Long-Lived Mouse and Caenorhabditis elegans Mutants Revealed by Statistical Analysis of Mortality Rates.

Hughes BG, Hekimi S.

Genetics. 2016 Nov;204(3):905-920. doi: 10.1534/genetics.116.192369. Epub 2016 Sep 16.

30.

Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes.

Fan X, Hughes BG, Ali MA, Chan BY, Launier K, Schulz R.

Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H183-9. doi: 10.1152/ajpheart.00229.2016. Epub 2016 May 6.

31.

Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart.

Baghirova S, Hughes BG, Poirier M, Kondo MY, Schulz R.

J Mol Cell Cardiol. 2016 May;94:153-161. doi: 10.1016/j.yjmcc.2016.04.004. Epub 2016 Apr 11.

PMID:
27079252
32.

Validation of an updated evidence-based protocol for proactive gastrostomy tube insertion in patients with head and neck cancer.

Brown TE, Getliffe V, Banks MD, Hughes BG, Lin CY, Kenny LM, Bauer JD.

Eur J Clin Nutr. 2016 May;70(5):574-81. doi: 10.1038/ejcn.2015.230. Epub 2016 Feb 10.

PMID:
26862007
33.

Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells.

Baghirova S, Hughes BG, Hendzel MJ, Schulz R.

MethodsX. 2015 Nov 7;2:440-5. doi: 10.1016/j.mex.2015.11.001. eCollection 2015.

34.

A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial.

Davidson A, Veillard AS, Tognela A, Chan MM, Hughes BG, Boyer M, Briscoe K, Begbie S, Abdi E, Crombie C, Long J, Boyce A, Lewis CR, Varma S, Broad A, Muljadi N, Chinchen S, Espinoza D, Coskinas X, Pavlakis N, Millward M, Stockler MR; Australasian Lung cancer Trials Group (ALTG); Australasian Lung cancer Trials Group ALTG.

Ann Oncol. 2015 Nov;26(11):2280-6. doi: 10.1093/annonc/mdv373. Epub 2015 Sep 7.

35.

New radiotherapy techniques do not reduce the need for nutrition intervention in patients with head and neck cancer.

Brown T, Banks M, Hughes BG, Lin C, Kenny LM, Bauer JD.

Eur J Clin Nutr. 2015 Oct;69(10):1119-24. doi: 10.1038/ejcn.2015.141. Epub 2015 Aug 26.

PMID:
26306565
36.

Improving guideline sensitivity and specificity for the identification of proactive gastrostomy placement in patients with head and neck cancer.

Brown TE, Crombie J, Spurgin AL, Tripcony L, Keller J, Hughes BG, Dickie G, Kenny LM, Hodge RA.

Head Neck. 2016 Apr;38 Suppl 1:E1163-71. doi: 10.1002/hed.24184. Epub 2015 Aug 13.

PMID:
26268152
37.

Dynamic Alterations to α-Actinin Accompanying Sarcomere Disassembly and Reassembly during Cardiomyocyte Mitosis.

Fan X, Hughes BG, Ali MA, Cho WJ, Lopez W, Schulz R.

PLoS One. 2015 Jun 15;10(6):e0129176. doi: 10.1371/journal.pone.0129176. eCollection 2015.

38.

Swallowing outcomes and PEG dependence in head and neck cancer patients receiving definitive or adjuvant radiotherapy +/- chemotherapy with a proactive PEG: a prospective study with long term follow up.

Crombie JM, Ng S, Spurgin AL, Ward EC, Brown TE, Hughes BG.

Oral Oncol. 2015 Jun;51(6):622-8. doi: 10.1016/j.oraloncology.2015.03.006. Epub 2015 Apr 10.

PMID:
25865554
39.

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.

Chan BA, Hughes BG.

Transl Lung Cancer Res. 2015 Feb;4(1):36-54. doi: 10.3978/j.issn.2218-6751.2014.05.01. Review.

40.

Compensatory elevation of voluntary activity in mouse mutants with impaired mitochondrial energy metabolism.

Lapointe J, Hughes BG, Bigras E, Hekimi S.

Physiol Rep. 2014 Nov 20;2(11). pii: e12214. doi: 10.14814/phy2.12214. Print 2014 Nov 1.

41.

Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma.

Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, Zarate D, Simpson F, Porceddu SV.

Ann Oncol. 2014 Oct;25(10):2047-52. doi: 10.1093/annonc/mdu368. Epub 2014 Aug 4.

42.

Targeting MMP-2 to treat ischemic heart injury.

Hughes BG, Schulz R.

Basic Res Cardiol. 2014 Jul;109(4):424. doi: 10.1007/s00395-014-0424-y. Epub 2014 Jul 2. Review.

PMID:
24986221
43.

Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma.

Hansen AR, Hughes BG, Paul S, Steadman P, Sommerville S, Dickinson IC, Walpole ET, Thomson DB, Mar Fan HG, Joubert WL.

Asia Pac J Clin Oncol. 2016 Jun;12(2):e222-8. doi: 10.1111/ajco.12167. Epub 2014 Feb 20.

PMID:
24571381
44.

MMP-2 is localized to the mitochondria-associated membrane of the heart.

Hughes BG, Fan X, Cho WJ, Schulz R.

Am J Physiol Heart Circ Physiol. 2014 Mar 1;306(5):H764-70. doi: 10.1152/ajpheart.00909.2013. Epub 2013 Dec 27.

45.

Validated swallowing and nutrition guidelines for patients with head and neck cancer: identification of high-risk patients for proactive gastrostomy.

Brown TE, Spurgin AL, Ross L, Tripcony L, Keller J, Hughes BG, Hodge R, Walker Q, Banks M, Kenny LM, Crombie J.

Head Neck. 2013 Oct;35(10):1385-91. doi: 10.1002/hed.23146. Epub 2012 Sep 13.

PMID:
22972623
46.

Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution.

Hughes BG, Jain VK, Brown T, Spurgin AL, Hartnett G, Keller J, Tripcony L, Appleyard M, Hodge R.

Head Neck. 2013 Mar;35(3):436-42. doi: 10.1002/hed.22992. Epub 2012 May 18.

PMID:
22605643
47.

Quality-of-life among head and neck cancer survivors at one year after treatment--a systematic review.

So WK, Chan RJ, Chan DN, Hughes BG, Chair SY, Choi KC, Chan CW.

Eur J Cancer. 2012 Oct;48(15):2391-408. doi: 10.1016/j.ejca.2012.04.005. Epub 2012 May 12. Review.

PMID:
22579456
48.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR.

Clin Cancer Res. 2012 Apr 15;18(8):2391-401. doi: 10.1158/1078-0432.CCR-11-3148. Epub 2012 Apr 5.

49.

Challenging the distal-to-proximal cannulation technique for administration of anticancer therapies: a prospective cohort study.

Chan RJ, Alexander A, Bransdon M, Webster J, Hughes BG, Brown L, Graham T.

Cancer Nurs. 2012 Sep-Oct;35(5):E35-40.

PMID:
22067699
50.

A mild impairment of mitochondrial electron transport has sex-specific effects on lifespan and aging in mice.

Hughes BG, Hekimi S.

PLoS One. 2011;6(10):e26116. doi: 10.1371/journal.pone.0026116. Epub 2011 Oct 10.

Supplemental Content

Loading ...
Support Center